Contributions
Abstract: PB1709
Type: Publication Only
Background
Identify prognostic biomarker is benefit to acute myeloid leukemia (AML) stratification and making individual therapeutic strategies.
Aims
We try to demonstrated the prognostic biomarker of acute myeloid leukemia (AML) and gene regulation pattern.
Methods
We analyzed general clinical information of AML, detected prognostic impact and gene regulation pattern of ALDH1A1 from The Cancer Genome Atlas (TCGA) dataset.
Results
The most highly incident rate of AML patients was at sixties’. More than half of patients were intermediate risk by NCCN stratification. Fms-like tyrosine kinase-3 (FLT3) was the most frequent mutation gene. Patients less than 60 years old and M3 type in French-American-British (FAB) classification were independent favorable prognostic factors, but not the gender, peripheral or bone marrow blast count, white blood cell count, hemoglobin concentration or platelet count. The expression of ALDH1A1 was associated with risk stratification and could be as a prognostic impact biomarker in AML. Knocking down ALDH1A1 affected leukemia cell survival and self-renewal property. The expression of ALDH1A1 was correlated to the expression of ITGB3 and could be regulated by integrin αvβ3.
Conclusion
Our study demonstrated TCGA is a high fidelity dataset for AML research and ALDH1A1 is a prognostic factor which could be regulated by integrin αvβ3.
Session topic: 3. Acute myeloid leukemia - Biology & Translational Research
Keyword(s): Acute Myeloid Leukemia, Aldehyde dehydrogenase, Integrin, Prognostic factor
Abstract: PB1709
Type: Publication Only
Background
Identify prognostic biomarker is benefit to acute myeloid leukemia (AML) stratification and making individual therapeutic strategies.
Aims
We try to demonstrated the prognostic biomarker of acute myeloid leukemia (AML) and gene regulation pattern.
Methods
We analyzed general clinical information of AML, detected prognostic impact and gene regulation pattern of ALDH1A1 from The Cancer Genome Atlas (TCGA) dataset.
Results
The most highly incident rate of AML patients was at sixties’. More than half of patients were intermediate risk by NCCN stratification. Fms-like tyrosine kinase-3 (FLT3) was the most frequent mutation gene. Patients less than 60 years old and M3 type in French-American-British (FAB) classification were independent favorable prognostic factors, but not the gender, peripheral or bone marrow blast count, white blood cell count, hemoglobin concentration or platelet count. The expression of ALDH1A1 was associated with risk stratification and could be as a prognostic impact biomarker in AML. Knocking down ALDH1A1 affected leukemia cell survival and self-renewal property. The expression of ALDH1A1 was correlated to the expression of ITGB3 and could be regulated by integrin αvβ3.
Conclusion
Our study demonstrated TCGA is a high fidelity dataset for AML research and ALDH1A1 is a prognostic factor which could be regulated by integrin αvβ3.
Session topic: 3. Acute myeloid leukemia - Biology & Translational Research
Keyword(s): Acute Myeloid Leukemia, Aldehyde dehydrogenase, Integrin, Prognostic factor